We use cookies and other similar technologies (Cookies) to enhance your experience and to provide you with relevant content and ads. By using our website, you are agreeing to the use of Cookies. You can change your settings at any time. Cookie Policy.

Linguamatics Announces that AstraZeneca Extended its License to the I2E Semantic Knowledge-Discovery Platform

Originally published July 10, 2009

Linguamatics, a provider in enterprise text mining for the life science and other markets, recently announced that AstraZeneca, a customer of Linguamatics since 2003, has extended its license to the I2E semantic knowledge-discovery platform with a further multi-year deal. I2E provides flexible and scalable enterprise text mining within AstraZeneca's knowledge engineering strategy, and supports decision making at many points in the drug discovery process, including target selection, biomarker discovery and safety/toxicology. Financial details of the agreement were not disclosed.

"AstraZeneca's researchers need efficient access to relevant biomedical knowledge," commented Roger Hale, COO and Cofounder of Linguamatics. "I2E uses agile NLP-based text mining technology to provide high quality insights from literature sources in real-time, supporting key decisions with the right information at the right time."

To read full press release, click here

This BeyeNETWORK news item contains information from a recent press release by the company mentioned.